Michael Thirman
Associate Professor of Medicine · University of Chicago Medical Center
Credentials: · · ·
History
- 1987–1990
- 1986–1987
University of Minnesota Health
Research
Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia
New England Journal of Medicine · 2020 · 2,437 citations
The Lancet Oncology · 2018 · 630 citations
New England Journal of Medicine · 1993 · First of over 10 authors · 483 citations
24 papers
22 papers
18 papers
13 papers
13 papers
- JP
10 papers
9 papers · 2 as a fellow
9 papers
Grants
- 2017–2023
Instructive Role of MLL Fusion Proteins in Lineage Determination and Leukemogenesis
National Cancer Institute · R01
Contact PI · $3M · University of Chicago
- 2005–2010
Molecular Genetics of MLL-Associated Leukemia
National Cancer Institute · P01
Project lead · $1.3M · Loyola University Chicago
- 2004–2010
MLL Fusions and Cooperating Mutations in Acute Leukemia
National Cancer Institute · R01
Contact PI · $1.5M · University of Chicago
- 1999–2005
Genetic Analysis of the Mll-Ell Fusion Protein
National Cancer Institute · R01
Contact PI · $1.3M · University of Chicago
Clinical trials
- 2018–2027
Combination of Pembrolizumab With TGR-1202 in Patients With Relapsed/Refractory CLL and B-cell NHL
Principal investigator · Active not recruiting · Phase 1
University of Chicago
- 2021–2028
Site PI · Recruiting · Phase 3
National Cancer Institute (NCI)
- 2019–2027
Site PI · Recruiting · Phase 1, Phase 2
Syndax Pharmaceuticals